Objective: The aim was to review the clinical safety profile of lacidipine with the help of the
rather comprehensive datafile of the manufacturer-a novel approach which may be of some …

Objective We reviewed the clinical safety profile of lacidipine with the help of the rather
comprehensive data file of the manufacturer. Although a number of prospective, randomly …

Elderly patients are becoming a greater proportion of the hypertensive population. In
addition, they may respond differently to drugs, both pharmacodynam-ically and …

Summary Abstract Lacidipine (Caldine®, Lacimen®, Lacipil®, Midotens®, Motens®) is a
once-daily, orally-administered, lipophilic dihydropyridine calcium antagonist with an …

Selection of the appropriate dose of a new drug for initiation of treatment and then for
maintenance is a complicated task. It requires the careful assessment and weighing of …

This multicenter study was designed to assess the clinical efficacy and safety of the new
once-daily calcium antagonist lacidipine in the treatment of mild-to-moderate essential …

Aim: To compare the vascular effects of lacidipine with those of other calcium antagonists.
Methods: A review of published studies. Results: Experimental studies have shown that for a …

Hypertension is well recognized to be an important cardiovascular risk factor and
antihypertensive therapy has been shown to decrease cardiovascular mortality and …

1. The aim of this randomised, double‐blind four way crossover study was to assess the
interaction between the new calcium antagonist, lacidipine and atenolol, in patients with …

The evaluation of haemodynamic patterns in hypertensive patients by radionuclide
techniques and a tomographic gamma camera has revealed differences between older and …